Journal
LEUKEMIA & LYMPHOMA
Volume 58, Issue 11, Pages 2565-2572Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1306645
Keywords
Risk factors; VRE; acute myeloid leukemia
Categories
Funding
- National Institutes of Health [UL1TR001857]
Ask authors/readers for more resources
We conducted a retrospective study to determine the risk factors associated with vancomycin-resistant enterococci (VRE) acquisition/infection in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome patients undergoing chemotherapy with the 7+3 regimen of cytarabine and idarubicin. Although only 2.5% (6/235) patients were colonized with VRE on admission, 59% (134/229) of patients acquired VRE during their hospitalization. Multivariable analysis identified the use of intravenous vancomycin (p=.024; HR: 1.548) and cephalosporin (p=.009; HR: 1.596) as the risk factors for VRE acquisition. VRE infection developed in 14% (33/229) of patients, with bloodstream infections accounting for 82% (27/33) of cases. VRE infection occurred in 25/126 (20%) of the VRE-colonized patients, but only 8/103 (8%) of those who were not (p=.01). Our study provides the evidence for the role of intravenous cephalosporin and vancomycin in VRE acquisition and highlights the clinical significance of VRE colonization in these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available